NVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today, Novo Nordisk A/S's share price is $40.81. Novo Nordisk A/S's Book Value per Share for the quarter that ended in Jun. 2016 was $2.53. Hence, Novo Nordisk A/S's P/B Ratio of today is 16.15.
During the past 13 years, Novo Nordisk A/S's highest P/B Ratio was 31.90. The lowest was 3.68. And the median was 8.50.
During the past 12 months, Novo Nordisk A/S's average Book Value Per Share Growth Rate was 11.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 1.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 3.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 7.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Novo Nordisk A/S was 17.70% per year. The lowest was -2.30% per year. And the median was 7.60% per year.
Novo Nordisk A/S's P/B ratio for today is calculated as follows:
|P/B Ratio||=||Share Price||/||Book Value per Share (Q: Jun. 2016)|
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book Ratio. The difference between Price-to-Tangible-Book Ratio and Price-to-Book Ratio is that book value other than intangibles are used in the calculation.
Unlike valuation ratios relative to the earning power such as P/E ratio, P/S ratio or Price-to-Free-Cash-Flow ratio, the Price-to-Book Ratio measures the valuation of the stock relative to the underlying asset of the company.
The Price-to-Book Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Novo Nordisk A/S Annual Data
Novo Nordisk A/S Quarterly Data